- United States
- /
- Medical Equipment
- /
- NasdaqCM:AEMD
Aethlon Medical Third Quarter 2023 Earnings: US$0.12 loss per share (vs US$0.16 loss in 3Q 2022)
Aethlon Medical (NASDAQ:AEMD) Third Quarter 2023 Results
Key Financial Results
- Net loss: US$2.85m (loss widened by 13% from 3Q 2022).
- US$0.12 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Aethlon Medical Earnings Insights
Looking ahead, revenue is expected to decline by 124% p.a. on average during the next 3 years, while revenues in the Medical Equipment industry in the US are expected to grow by 7.5%.
Performance of the American Medical Equipment industry.
The company's shares are down 14% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 6 warning signs with Aethlon Medical (at least 3 which are concerning), and understanding these should be part of your investment process.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:AEMD
Aethlon Medical
A medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States.
Medium-low risk with mediocre balance sheet.
Market Insights
Weekly Picks

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fiducian: Compliance Clouds or Value Opportunity?
Willamette Valley Vineyards (WVVI): Not-So-Great Value
Recently Updated Narratives
Watch Pulse Seismic Outperform with 13.6% Revenue Growth in the Coming Years
Significantly undervalued gold explorer in Timmins, finally getting traction
Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08
Popular Narratives

MicroVision will explode future revenue by 380.37% with a vision towards success

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
